Glyscend Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$10M
- Investors
-
13
Glyscend Therapeutics General Information
Description
Developer of gut-targeted polymer therapeutics designed for the treatment of metabolic indications such as type 2 diabetes and other chronic conditions. The company offers an orally administered drug, which is non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety advantages, enabling patients to avoid invasive complications of surgeries and procedures.
Contact Information
Website
www.glyscend.comCorporate Office
- 1812 Ashland Avenue
- Suite 110
- Baltimore, MD 21205
- United States
Corporate Office
- 1812 Ashland Avenue
- Suite 110
- Baltimore, MD 21205
- United States
Glyscend Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 23-Mar-2023 | $10M | Completed | Clinical Trials - Phase 2 | ||
| 7. Later Stage VC (Series A) | 23-Oct-2019 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 01-Aug-2019 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 18-Sep-2017 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 01-Jul-2015 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | 05-May-2015 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 01-Sep-2014 | $165K | Completed | Startup | ||
| 1. University Spin-Out | 01-Jan-2014 | Completed | Startup |
Glyscend Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Glyscend Therapeutics Patents
Glyscend Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220378886-A1 | Methods of treating hyperoxaluria | Inactive | 06-Nov-2019 | ||
| EP-4041740-A1 | Benzoxaborole polymers and methods of use | Inactive | 20-Sep-2019 | ||
| EP-4041740-A4 | Benzoxaborole polymers and methods of use | Inactive | 20-Sep-2019 | ||
| JP-2025019142-A | Benzoxaborole polymers and methods of use | Pending | 20-Sep-2019 | ||
| US-20220396651-A1 | Benzoxaborole polymers and methods of use | Inactive | 20-Sep-2019 | C08F230/06 |
Glyscend Therapeutics Signals
Glyscend Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brandon Biocatalyst | Venture Capital | Minority | ||
| Brandon Capital | Venture Capital | Minority | ||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | Minority | ||
| Santé Ventures | Venture Capital | Minority | ||
| Breakout Labs | Not-For-Profit Venture Capital | Minority |
Glyscend Therapeutics FAQs
-
When was Glyscend Therapeutics founded?
Glyscend Therapeutics was founded in 2014.
-
Where is Glyscend Therapeutics headquartered?
Glyscend Therapeutics is headquartered in Baltimore, MD.
-
What is the size of Glyscend Therapeutics?
Glyscend Therapeutics has 16 total employees.
-
What industry is Glyscend Therapeutics in?
Glyscend Therapeutics’s primary industry is Drug Discovery.
-
Is Glyscend Therapeutics a private or public company?
Glyscend Therapeutics is a Private company.
-
What is the current valuation of Glyscend Therapeutics?
The current valuation of Glyscend Therapeutics is .
-
What is Glyscend Therapeutics’s current revenue?
The current revenue for Glyscend Therapeutics is .
-
How much funding has Glyscend Therapeutics raised over time?
Glyscend Therapeutics has raised $30.5M.
-
Who are Glyscend Therapeutics’s investors?
Brandon Biocatalyst, Brandon Capital, Johnson & Johnson Innovation - JLABS, Santé Ventures, and Breakout Labs are 5 of 13 investors who have invested in Glyscend Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process